Rational Combination of Parvovirus H1 With CTLA-4 and PD-1 Checkpoint Inhibitors Dampens the Tumor Induced Immune Silencing.
H-1PV
immune cells
immunotherapy
ipilimumab
melanoma
nivolumab
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2019
2019
Historique:
received:
21
01
2019
accepted:
07
05
2019
entrez:
14
6
2019
pubmed:
14
6
2019
medline:
14
6
2019
Statut:
epublish
Résumé
The recent therapeutic success of immune checkpoint inhibitors in the treatment of advanced melanoma highlights the potential of cancer immunotherapy. Oncolytic virus-based therapies may further improve the outcome of these cancer patients. A human
Identifiants
pubmed: 31192129
doi: 10.3389/fonc.2019.00425
pmc: PMC6546938
doi:
Types de publication
Journal Article
Langues
eng
Pagination
425Références
Cancer Gene Ther. 2001 Mar;8(3):158-67
pubmed: 11332986
Cancer Gene Ther. 2003 Jun;10(6):477-80
pubmed: 12768193
Blood. 2004 Apr 1;103(7):2677-82
pubmed: 14630824
Methods Mol Med. 2005;109:285-96
pubmed: 15585928
Int J Cancer. 2005 Nov 20;117(4):538-50
pubmed: 15912538
Hum Gene Ther. 2005 Aug;16(8):996-1005
pubmed: 16076257
Mol Cell Biol. 2005 Nov;25(21):9543-53
pubmed: 16227604
Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):16013-8
pubmed: 16247014
Trends Immunol. 2008 Jun;29(6):272-9
pubmed: 18468488
Clin Cancer Res. 2009 Jan 15;15(2):511-9
pubmed: 19147756
Hum Immunol. 2010 Oct;71(10):934-41
pubmed: 20650297
J Immunol. 2010 Sep 1;185(5):2790-9
pubmed: 20686126
BMC Cancer. 2011 Oct 26;11:464
pubmed: 22029859
Lancet Oncol. 2012 Jan;13(1):e32-42
pubmed: 22225723
PLoS One. 2012;7(2):e32197
pubmed: 22359669
Cancer Res. 2012 Jul 1;72(13):3125-30
pubmed: 22721837
Int J Cancer. 2013 Jun 1;132(11):2548-56
pubmed: 23151948
J Transl Med. 2013 May 01;11:108
pubmed: 23634660
Onco Targets Ther. 2013 Aug 20;6:1119-27
pubmed: 23986643
J Virol. 2014 May;88(10):5263-76
pubmed: 24574398
Front Oncol. 2014 May 01;4:92
pubmed: 24822170
Cancer Immunol Res. 2015 Apr;3(4):399-411
pubmed: 25678581
Curr Treat Options Oncol. 2015 Mar;16(3):326
pubmed: 25777572
Cell. 2015 Sep 10;162(6):1242-56
pubmed: 26359984
Mol Oncol. 2015 Dec;9(10):1936-65
pubmed: 26578451
Ann Transl Med. 2015 Oct;3(18):267
pubmed: 26605313
Viruses. 2015 Dec 09;7(12):6506-25
pubmed: 26690204
J Exp Med. 1989 Sep 1;170(3):797-810
pubmed: 2788708
Onco Targets Ther. 2017 May 02;10:2389-2401
pubmed: 28496337
Hum Gene Ther. 2017 Oct;28(10):800-819
pubmed: 28870120
Mol Ther. 2017 Dec 6;25(12):2620-2634
pubmed: 28967558
Cancer Res. 2018 Jan 15;78(2):436-450
pubmed: 29150430
Viruses. 2017 Dec 15;9(12):
pubmed: 29244745
Hum Vaccin Immunother. 2018 Apr 3;14(4):839-846
pubmed: 29420123
J Immunother Cancer. 2018 May 16;6(1):36
pubmed: 29764498
Melanoma Res. 2018 Oct;28(5):371-379
pubmed: 29957656
Int J Cancer. 1993 Sep 9;55(2):237-44
pubmed: 7690346
J Exp Med. 1994 Jul 1;180(1):35-42
pubmed: 8006593
Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):5915-9
pubmed: 8650193
Immunity. 1996 Jun;4(6):535-43
pubmed: 8673700
J Exp Med. 1996 Jun 1;183(6):2533-40
pubmed: 8676074
Eur J Immunol. 1997 Dec;27(12):3135-42
pubmed: 9464798